Ray M D, Kapoor Rohan, Banthia Pranjal
Department of Surgical Oncology, All India Institute of Medical Sciences, New Delhi, India.
Department of Surgical Oncology, All India Institute of Medical Sciences, New Delhi, India.
Eur J Obstet Gynecol Reprod Biol. 2025 Aug;312:114113. doi: 10.1016/j.ejogrb.2025.114113. Epub 2025 Jun 7.
Ovarian cancer is the deadliest gynaecological malignancy, often diagnosed at an advanced stage with widespread peritoneal dissemination and lymph node involvement, particularly in retroperitoneal and pelvic regions. The Peritoneal Cancer Index(PCI) is used to assess peritoneal disease but does not address nodal metastasis, an important prognostic factor. The Nodal Cancer Index(NCI) was developed to quantify lymph node burden, improving surgical precision.
The primary aim was to assess the NCI as a score for objectively evaluating systemic lymph node dissection in ovarian cancer. Secondary objectives included evaluating its prognostic value and survival outcomes.
This study included 211 patients with advanced ovarian cancer(FIGO stages III and IV) who underwent cytoreductive surgery(CRS) from 2015 to 2020. The NCI divided the abdomen and pelvis into 13 nodal zones zones(6 retroperitoneal and 6 pelvic, plus an extra-abdominal zone). Each zone was scored based on lymph node size, with higher scores indicating more extensive disease. The NCI score was correlated with clinical outcomes, including survival rates.
The cohort's median age was 51 years, with most patients at advanced stages (FIGO III: 73.9 %, IV: 26.1 %). Histologically, 83.4 % had serous carcinoma. Treatment included 23.7 % upfront surgery and 76.3 % neoadjuvant chemotherapy (NACT) with interval cytoreductive surgery (CC-0: 88.1 %). Lymph node involvement occurred in 46.4 % of cases. Survival analysis showed that patients with low, moderate, and severe NCI scores had median OS of 57.70, 47.58, and 36.37 months, respectively, with lower NCI scores linked to better survival.
The NCI provides an objective framework for assessing lymph node metastasis in ovarian cancer, aiding in surgical planning, prognostication, and treatment decisions.
卵巢癌是最致命的妇科恶性肿瘤,通常在晚期被诊断出来,伴有广泛的腹膜播散和淋巴结受累,尤其是在腹膜后和盆腔区域。腹膜癌指数(PCI)用于评估腹膜疾病,但未涉及淋巴结转移这一重要的预后因素。淋巴结癌指数(NCI)旨在量化淋巴结负荷,提高手术精准度。
主要目的是评估NCI作为客观评估卵巢癌系统性淋巴结清扫的评分。次要目标包括评估其预后价值和生存结果。
本研究纳入了2015年至2020年期间接受减瘤手术(CRS)的211例晚期卵巢癌(国际妇产科联盟(FIGO)分期III和IV期)患者。NCI将腹部和盆腔分为13个淋巴结区域(6个腹膜后区域、6个盆腔区域以及1个腹外区域)。每个区域根据淋巴结大小进行评分,分数越高表明疾病范围越广。NCI评分与包括生存率在内的临床结果相关。
该队列的中位年龄为51岁,大多数患者处于晚期(FIGO III期:73.9%,IV期:26.1%)。组织学上,83.4%为浆液性癌。治疗包括23.7%的 upfront手术和76.3%的新辅助化疗(NACT)以及间隔减瘤手术(CC-0:88.1%)。46.4%的病例发生淋巴结受累。生存分析表明,NCI评分低、中和高的患者的中位总生存期分别为57.70、47.58和36.37个月,NCI评分越低,生存率越高。
NCI为评估卵巢癌淋巴结转移提供了一个客观框架,有助于手术规划、预后评估和治疗决策。